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Abstract
Objective: To determine the correlation between Glycated 
Albumin concentrations with the outcome of pregnant 
women with Type 2 Diabetes Mellitus in Zainoel Abidin 
Hospital, Banda Aceh. 
Methods: This was an observational correlational study 
using a cross-sectional design. Subjects include pregnant 
women with a history of Type 2 Diabetes Mellitus who are 
examined for serum GA levels using colorimetric enzymatic 
methods and the outcomes will be assessed during 
pregnancy. Data analysis was performed using the ETA test 
and Receiver Operating Characteristic (ROC) curve.
Results: A total of 29 subjects with a mean age of 33.25 
years had normal maternal outcome and those with a 
mean age of 34.92 years had abnormal maternal outcome. 
Statistically there was a signifi cant correlation between 
GA levels and the maternal outcome of pregnant women 
with Type 2 Diabetes Mellitus (p = 0.009) with a moderate 
degree of negative correlation (r = 0.477). The GA cut-off 
for pregnancy outcome is 16.77% with a sensitivity and 
specifi city of 76% and 75% respectively.
Conclusions: Examination of GA concentration can be 
used as a predictor to assess maternal outcomes during 
pregnancy with moderate correlation and a cutoff point of 
16.77%.
Keywords: diabetes mellitus, glycated albumin, maternal 
outcome, pregnancy. 
Abstrak
Tujuan: Untuk mengetahui korelasi kadar Glycated Albumin 
terhadap outcome pada ibu hamil yang menderita diabetes 
melitus tipe I dan untuk mengetahui berapa kadar Glycated 
Albumin yang dapat memberikan hasil buruk pada ibu hamil 
yang menderita diabetes melitus tipe II di RSUD dr. Zainoel 
Abidin Banda Aceh.
Metode: Penelitian ini merupakan studi korelatif 
observasional menggunakan desain potong lintang. 
Perempuan hamil dengan riwayat DMT2 akan diperiksan 
kadar GA serum menggunakan metode enzimatik 
kolorimetri serta akan dinilai outcome selama kehamilan. 
Analisis data dilakukan menggunakan uji Eta dan kurva 
Receiver Operating Characteristic (ROC) dengan tingkat 
kepercayaan 95%. 
Hasil: Sebanyak 29 subjek dengan rerata usia 33,25 tahun 
(hasil normal) dan 34,92 tahun (hasil kelainan). Secara 
statistik terdapat korelasi yang bermakna antara kadar 
GA dan outcome ibu penderita DMT2 (p = 0,009) dengan 
derajat korelasi sedang (r = 0,477) dengan arah korelasi 
negatif. Titik potong GA terhadap outcome kehamilan 
adalah 16,77% dengan sensitifi tas dan spesisitas secara 
berurutan 76% dan 75%.
Kesimpulan: Pemeriksaan GA dapat dijadikan sebagai 
prediktor untuk menilai outcome ibu selama kehamilan 
dengan tingkat korelasi sedang dan titik potong 16,77%.
Kata kunci: diabetes melitus, glikasi albumin, hamil, luaran 
ibu.
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Type 2 diabetes is characterized by 
hyperglycemia and results from a combination of 
insulin resistance, inadequate insulin secretion, 
and excessive or inappropriate glucagon secretion. 
Uncontrolled type 2 diabetes is associated 
with various microvascular, macrovascular and 
neuropathic complications. Unlike patients with 
type 1 diabetes mellitus, patients with type 2 
are not completely dependent on insulin for 
life. Diabetes mellitus is a chronic disease that 
requires long-term medical attention in order to 
prevent complications which may occur.1
The prevalence of diabetes is increasing 
worldwide. The International Diabetes Federation 
predicts that the number of people living with 
diabetes will increase from 366 million in 2011 to 
552 million in 2030.2 The top ten countries with 
leading incidences of diabetes today include 
India, China, the United States, Indonesia, Japan, 
Pakistan, Russia, Brazil, Italy and Bangladesh. The 
biggest increase in diabetes will occur in Africa 
over the next 20 years. About 80% of people in 
Africa with diabetes are undiagnosed and many 
cases occur at the age of 30 to 60 years with high 
mortality rates.1
Optimal control of blood sugar levels in 
the fi rst and second trimesters of pregnancy 
is important to prevent complications in both 
the mother and fetus. The American Diabetes 
Association and the UK National Institute for 
Health and Care Excellence encourages proper 
glycemic control for women with type 1 diabetes 
during early pregnancy ( recommended HbA1c 
levels <48 mmol / mol [<6.5%] ).3 Maternal 
infl uences due to diabetes can be subdivided 
during pregnancy, labor and puerperium. 
During pregnancy, diabetes can cause abortion, 
preeclampsia, polyhydramnios, premature labor 
and increased risk of pelvic head disproportion 
and malpresentation. During labor, diabetic 
complications include prolonged labor due to 
macrosomia, shoulder dystocia, increased risk 
for operation, rupture of the birth canal and 
postpartum hemorrhage. During pueperium, 
puerperal sepsis caused by immunocompromised 
conditions in pregnant women with diabetes 
may occur and can increase maternal morbidity. 
Effects of diabetes on the fetus include Fetus 
intrauterine death of the fetus, Macrosomia, late 
pulmonary maturation, birth trauma, growth 
retardation, congenital malfromation, and 
increased neonatal mortality.
Optimal maintenance of blood glucose 
levels is known to be associated with decreased 
complications in diabetes mellitus. In 2010 the 
American Diabetes Association (ADA) included 
HbA1c levels in the diagnostic criteria of Diabetes 
and recommend that HbA1C examination should 
be performed to control diabetic complications.4-6 
It has recently been reported that there are 
biomarkers that are more sensitive than HbA1C 
to indicate diabetes, namely Glycated Albumin 
(GA). Glycated Albumin was declared 10 times 
more sensitive than HbA1C in a study which 
examined a group of diabetics before and after 
undergoing diabetes therapy. The aim of this 
research is to fi nd out whether glycated albumin 
levels is correlated with maternal outcome in 
pregnant women suffering from type II diabetes 
mellitus at the Regional General Hospital (RSUD) 
Dr. Zainoel Abidin Banda Aceh.
METHODS
This was a cross sectional design. The aim 
of this study is to determine the correlation 
between Glycated Albumin levels and the 
maternal outcome of pregnant women with Type 
2 Diabetes. This research was conducted in the 
delivery suite of the Dr. Zainoel Abidin (RSUZA) 
General Hospital Banda Aceh from 4th January 
2019 to 4th January 2020. Laboratory tests for 
Glycated Albumin levels were conducted at the 
Prodia Laboratory in Banda Aceh.
Inclusion criteria include a diagnosis of Diabetes 
Type 2 in pregnant women aged between 18 to 
39 years old which is confi rmed by an Internal 
Medicine Specialist. Exclusion criteria include: 
twin pregnancies, consumption of medication 
which affect pregnancies (for example, drugs 
which cause abortion and disruption of fetal organ 
development), pregnant women with congenital 
heart defects, autoimmune disease, malnutrition 
and placental and uterine abnormalities. 
Blood specimens for examination of Glycated 
Albumin levels were taken from mediana cubital 
vein. About 3 ml was inserted into a serum 
separator tube and sent to the Banda Aceh 
Prodia Laboratory. Glycated albumin levels were 
assessed using colorimetric enzymatic method. 
The diagnosis of Diabetes Type 2 is made by an 
Internal Medicine Specialist. All data collected are 
analysed further using the ETA test and Receiver 
Operating Characteristic (ROC) curve. 
RESULTS
There were 29 pregnant women suffering 
from type 2 diabetes mellitus who fulfi lled the 
subject inclusion criteria. General characteristics 
of respondents and its respective maternal 
outcome are as follows:
The distribution of parity and diagnosis are 
presented in the table above. The group with 
normal outcomes is dominated by the parity 
G1 and G5, P1 and A0, while the group with 
abnormalities is dominated by G3P1A0. Most 
groups of pregnant women with abnormalities 
had a diagnosis of severe preeclampsia (33.3%) 
and macrosomia (16.7%) and also Preterm Labor, 
IUGR and premature labor with an incidence 
percentage of 8.3% each.
Table 1. General Characteristics of Respondents and its Respective Maternal Outcome
Age of Mother (years)
Gestational Age (weeks)
Body Mass Index (Kg/m2)
Fasting Blood Glucose Concentration (mg/dL)
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The diagram above shows the Receiver 
Operating Characteristic (ROC) curve which 
shows the Area Under Curve (AUC) of 0.860. 
Based on these values it can be concluded that 
GA examination can be used as a predictor of 
pregnancy outcome in women suffering from 
type II DM with a discrimination rate of 86%. 
Furthermore, by using the coordinate of the 
curve, the GA intersection point is statistically 
16.77%. The sensitivity and specifi city values of 
the cut points are 76% and 75% respectively.
the second and third trimesters, maternal 
hyperinsulinemia can cause fetal hyperglycemia, 
hyperinsulinemia, myocardial hypertrophy, delay 
of pulmonary maturation and macrosomia.7
At present the gold standard for checking 
glucose levels is by measuring the levels of 
glycated hemoglobin (HbA1C). This examination 
provides information of varying blood glucose 
levels during the last 2 to 3 months. However, 
HbA1C levels are as dependent on the abnormal 
life span of erythrocytes as they are with iron 
defi ciency anemia. Pregnant women with 
diabetes mellitus or gestational diabetes mellitus 
often have iron defi ciency anemia, making the 
HbA1C examination inaccurate.8,9
In general, maternal outcomes can be divided 
into three, namely during pregnancy, labor 
and puerperium. Outcome during pregnancy 
can be in the form of abortion, preeclampsia, 
polyhydramnios, preterm labor. During labor 
in the form of prolonged labor due to a large 
baby, shoulder dystocia, ruptured birth canal 
and postpartum hemorrhage. Puerperal sepsis 
caused by immunocompromised conditions 
in pregnant women with diabetes can increase 
meternal morbidity. Furthermore, negative 
effects which may occur to the fetus include IUFD, 
macrosomia, late lung maturation, birth trauma, 
growth retardation, congenital malfromation, 
and increased neonatal mortality.4
The condition of hyperglycemia in the fetus 
occurs when the maternal pancreatic insulin 
response is inadequate, this manifests as a 
recurring postprandial hyperglycemic episode. 
This postprandial episode is a major cause of 
rapid growth in the fetus. Maternal and fetal blood 
glucose levels are accompanied by episodic fetal 
hyperinsulinemia. Fetal hyperinsulinemia causes 
an increase in the storage of excess nutrients, 
causing macrosomia. Energy expenditure 
associated with the conversion of excess glucose 
into fat causes depletion of fetal oxygen levels. 
These episodes of fetal hypoxia are accompanied 
by increased adrenal catecholamines, which 
cause hypertension, cardiac remodeling and 
hypertrophy, erythropoietin stimulation, red 
blood cell hyperplasia, and increased hematocrit 
concentration. Polycythaemia occurs in 5-10% of 
newborns of diabetic mothers. High hematocrit 
values in neonates cause vascular sludging, poor 
circulation, and postnatal hyperbilirubinemia.10
Adverse effects due to abnormal maternal 
metabolism in offspring have also been 
observed. Glucose intolerance and higher serum 
Based on the ETA correlative test results 
above, it can be concluded that there is a 
correlation between glycated albumin levels and 
the outcome of mothers suffering from type 
II diabetes with a signifi cance level of 0.009. 
Correlation coeffi cient values between the two 
variables indicate medium strength with a value 
of R = 0.477 with a negative correlation.
DISCUSSION
Infants of diabetic mothers generally 
experience various complications related to 
fetal hyperinsulinemia induced by maternal 
hyperinsulinemia. In the fi rst trimester, maternal 
hyperinsulinemia can cause hyperinsulinemia 
embryopathy which can cause major disability 
and spontaneous abortion. Furthermore, in 
Figure 1. ROC Curve showing the correlation between 
Glycated Albumin and Maternal Outcome
Table 2. Analysis of the Correlation of Study Variables
Normal
Abnormal
12.54 (7.2 – 16.67)
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insulin levels are more common in children of 
diabetic mothers. Several literature supports 
the relationship between intrauterine exposure 
with diabetic mothers and the risk of metabolic 
syndrome later in life. Metabolic syndromes 
in childhood include obesity, hypertension, 
dyslipidemia, and glucose intolerance. Fetuses 
of diabetic women born with a large age for 
gestation appear to be at greatest risk.11
Children born to mothers with diabetes exhibit 
higher levels of cardiac biomarkers for endothelial 
damage, as well as higher levels of leptin, BMI, 
waist circumference, and systolic blood pressure. 
This relationship remained signifi cant even in 
pregnant women with a previously normal BMI.7
Diabetes management during pregnancy with 
continuous glucose monitoring (CGM) can reduce 
maternal hyperglycemia and macrosomia.12 
Maintaining normal blood glucose levels has 
been known to reduce the risk of maternal 
and neonatal complications during pregnancy. 
Referring to the study, monitoring of glucose 
levels using appropriate modalities is needed to 
improve neonatal and maternal outcomes during 
pregnancy and childbirth. A multicenter study 
concluded that GA examination is more superior 
for diabetes management during pregnancy than 
HbA1C.13
Glycated albumin (GA) is a ketoamine 
formed from albumin and glucose binded 
by non-enzymatic oxidation reaction, it is 
considered as an index of glycemic control that 
is not infl uenced by abnormalities in hemoglobin 
metabolism. Glycated albumin is able to monitor 
the administration of diabetes therapy and also 
anticipate earlier complications of DM. GA is not 
affected by albumin concentration because GA 
calculates the ratio of total serum albumin.12
However, before carrying out a GA examination 
on pregnant women, several factors which can 
affect serum albumin need to be considered. 
Serum GA levels are infl uenced by several factors 
associated with albumin regulation regardless of 
diabetes status such as thyroid dysfunction and 
cirrhosis. For example, thyroid hormone is known 
to play a role in albumin catabolism. Serum GA 
levels are positively correlated with serum TSH 
and negatively correlated to free T3 and T4. In 
addition, GA levels are also infl uenced by age 
and nutritional status.
Recent studies have reported the effectiveness 
of examining glycated albumin (GA) as a marker 
(biomarker) of glucose control in pregnant 
women. Compared to HbA1C, GA describes 
blood glucose levels with a shorter duration of 
2 to 3 weeks. GA is not affected by the life span 
of erythrocytes like HbA1C, so it is very useful 
during pregnancy.14 In addition to acting as a 
control of blood glucose levels, this study proves 
the correlation between GA levels on pregnancy 
outcomes in women suffering from type 2 
diabetes mellitus.
Similar to this study, Sugawara et al in 
2016 reported that GA examination served 
as a predictor of fetal complications during 
pregnancy. With a GA cutoff of 15.8% in the 
study, it was known that various neonatal 
complications such as hyperglycemia, respiratory 
distress, hypocalcemia, myocardial hypertrophy 
and macrosomia were identifi ed.15 However, the 
GA cutoff point obtained from this study which 
predicts maternal pregnancy outcomes with 
DMT2 was found greater than 16.7%.
CONCLUSION
Our study concludes that examination of 
Glycated Albumin concentration can be used as 
a predictor to assess maternal outcomes during 
pregnancy with a moderate correlation level and 
a cutoff point of 16.77%. 
SUGGESTION
Hopefully, this research can inspire more 
researchers to conduct more studies which 
reaffi rm the importance of Glycated Albumin as 
a screening modality and its ability to predict 
maternal outcome in pregnant women with Type 
2 Diabetes Mellitus.
ACKNOWLEDGEMENT
The author is very thankful to the Obstetrics and 
Gynecology and Internal Medicine Department of 
Faculty of Medicine in Syiah Kuala University, Dr. 
Zainoel Abidin General Hospital and also to the 
staff of Prodia Clinic in Banda Aceh for their help 
and collaboration on this research. This research 
does not have any confl ict of interest.
Vol 9. No 1. January 2021  Glycated Albumin as an Outcome 19
1. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman 
WH, Holst JJ, et al. Type 2 diabetes mellitus. Nature 
reviews Disease primers. 2015;1:15019.
2. Federation ID. One adult in ten will have diabetes by 
2030. IDF; 2011.
3. Schaefer-Graf U, Napoli A, Nolan CJ, Group DPS. 
Diabetes in pregnancy: a new decade of challenges 
ahead. Diabetol. 2018;61(5):1012-21.
4. Delamater AM. Clinical use of hemoglobin A1c 
to improve diabetes management. Clin Diabet. 
2006;24(1):6-8.
5. Gomez-Perez FJ, Aguilar-Salinas CA, Almeda-Valdes 
P, Cuevas-Ramos D, Garber IL, Rull JA. HbA1c for the 
diagnosis of diabetes mellitus in a developing country. 
A position article. Arch Med Research. 2010;41(4):302-8.
6. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, 
Kirkman MS, et al. Guidelines and recommendations for 
laboratory analysis in the diagnosis and management 
of diabetes mellitus. Clin Chemist. 2011;57(6):e1-e47.
7. Cheng Y, Caughey A. Gestational diabetes: diagnosis 
and management. J Perinatol. 2008;28(10):657.
8. Hashimoto K, Osugi T, Noguchi S, Morimoto Y, Wasada 
K, Imai S, et al. A1C but not serum glycated albumin is 
elevated because of iron defi ciency in late pregnancy in 
diabetic women. Diabetes care. 2010;33(3):509-11.
9. Juraschek SP, Steffes MW, Miller ER, Selvin E. Alternative 
markers of hyperglycemia and risk of diabetes. Diabet 
care. 2012;35(11):2265-70. 
10. Rahayu A, Rodiani R. Efek Diabetes Melitus Gestasional 
terhadap Kelahiran Bayi Makrosomia. J Major. 
2016;5(4):17-22.
11. Athukorala C, Crowther CA, Willson K, Group ACISiPWT. 
Women with gestational diabetes mellitus in the 
ACHOIS trial: risk factors for shoulder dystocia. Au New 
Zealand J ObsteT Gynecol. 2007;47(1):37-41.
12. Murphy HR, Rayman G, Lewis K, Kelly S, Johal B, Duffi eld 
K, et al. Effectiveness of continuous glucose monitoring 
in pregnant women with diabetes: randomised clinical 
trial. BMJ. 2008;337:a1680.
13. Shimizu I, Hiramatsu Y, Omori Y, Nakabayashi M, Group 
JS. Comparison of HbA1c and glycated albumin as a 
control marker for newborn complications in diabetic 
women in a multicentre study in Japan (Japan glycated 
albumin study group: study 2). Ann Clin Biochemist. 
2018;55(6):639-46.
14. Beck R, Steffes M, Xing D, Ruedy K, Mauras N, Wilson 
DM, et al. The interrelationships of glycemic control 
measures: HbA1c, glycated albumin, fructosamine, 1, 5
anhydroglucitrol, and continuous glucose monitoring. 
Pediatric Diabet. 2011;12(8):690-5.
15. Sugawara D, Maruyama A, Imanishi T, Sugiyama Y, 
Ichihashi K. Complications in infants of diabetic mothers 
related to glycated albumin and hemoglobin levels 
during pregnancy. Pediatr Neonatol. 2016;57(6):496-
500.
REFERENCES
20 Yeni, Lubis, Munawar and Zuffry
Indones J
Obstet Gynecol
